■ Celanese announced that it has entered into an agreement with Glaukos to supply its VitalDose drug delivery platform for use as a component to the Glaukos iDose TR investigational microinvasive intraocular implant. iDose TR is designed to lower intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension, and to address patient nonadherence and chronic side effects associated with topical medications by providing continuous, long-duration therapy. The VitalDose drug delivery platform facilitates the potential to provide continuous dosing, which can reduce issues related to patient compliance and adherence.

“The inclusion of our VitalDose platform in Glaukos iDose TR therapy furthers our mission to improve patient health in ophthalmology for those living with chronic eye diseases,” Cyonna Holmes, global business strategy leader for ophthalmology at Celanese, said in a news release.